Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 224

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 224
---
PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS (unaudited)

KEROS THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets 

(In thousands, except share and per share data) 

(Unaudited)

SEPTEMBER 30,2025DECEMBER 31,2024ASSETSCURRENT ASSETS:Cash and cash equivalents$693,472 $559,931 Accounts receivable 3,492 2,742 Prepaid expenses and other current assets22,343 26,220 Total current assets719,307 588,893 Operating lease right-of-use assets17,463 19,251 Property and equipment, net4,564 4,237 Restricted cash1,449 1,449 Other long-term assets— 2,056 TOTAL ASSETS$742,783 $615,886 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:Accounts payable$2,298 $4,602 Current portion of operating lease liabilities2,318 1,978 Accrued expenses and other current liabilities15,174 20,870 Deferred revenue155 — Current tax liability4,147 — Total current liabilities24,092 27,450 Operating lease liabilities, net of current portion15,111 16,883 Total liabilities39,203 44,333 STOCKHOLDERS' EQUITY:Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued and outstanding— — Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 and no shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding— — Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 40,632,164 and 40,554,705 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively4 4 Additional paid-in capital1,161,880 1,140,328 Accum